ArticleCancers2023

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis.

Ippazio Cosimo Antonazzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.